Phase I Non-Myeloablative Trial With 90Y-Humanized MN-14 (Anti-CEA) Antibody for Relapsed or Refractory Advanced Non-Small Cell Lung Cancer (NSCLC).
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Labetuzumab Y-90 (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 28 Feb 2009 Additional trial centres added reported by ClinicalTrials.gov, last updated 28 Feb 2009.
- 14 Sep 2005 New trial record.